NCT05664789View on ClinicalTrials.gov

Targeting the Neurobiology of RRB in Autism Using N-acetylcysteine: Trial

PHASE2/PHASE3RecruitingINTERVENTIONAL
Enrollment

144

Participants

Timeline

Start Date

April 26, 2023

Primary Completion Date

January 31, 2026

Study Completion Date

January 31, 2026

Conditions
Autism Spectrum Disorder
Interventions
DRUG

N acetyl cysteine

N-acetylcysteine (NAC) is an over-the-counter dietary supplement that is relatively well tolerated and exhibits minimal side effects, even at high dosages. N

DRUG

Placebo

matched placebo

Trial Locations (1)

94304

RECRUITING

Department of Psychiatry and Behavioral Sciences, Palo Alto

All Listed Sponsors
collaborator

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

NIH

lead

Stanford University

OTHER